has generated a broad-scoped and leading patent family around small
molecule inhibition of epigenetic factors related to single carbon
metabolism (methionine cycle) and other epigenomic modifying
targets affecting cellular reprogramming potential. Some of the same
epigenetic enzymes targeted by NuPotential's novel and proprietary NP-Epidrug libraries,
including histone deactylases (HDAC), sirtuins (SIRT), and histone
methyltransferases (HMT) are strongly associated with the underlying
causes of multiple human chronic diseases such as type 2 diabetes,
obesity, cancer, Alzheimer's and Parkinson's. As such,
NuPotential is leveraging its PIER and NP-Reprog platforms to broaden the current epidrug market with NP-Epidrugs, a highly selective, novel and proprietary class of pharmaceuticals that target epigenetic factors of chronic disease.
are drug-like, lead small molecule compounds developed to be first in
class, and best in class therapies of chronic diseases including
type 2 diabetes, obesity and cancer. NuPotential's "unique and
unprecedented" PIER epidrug discovery and NP-Reprog cell reprogramming platforms provide the company a clear advantage in uncovering NP-Epidrug targets involved in epigenomic maintenance ("Persistent Epigenetic Memory"). As a result, NP-Epidrugs can
be designed to selectively target disease pathways at their epigenetic
core to decouple aberrant epigenomic modifications that cause abnormal
physiologies associated with disease onset and progression.
Strong working relationships with reputable medicinal chemistry CRO's
ensures that all lead NP-Epidrugs
are synthesized and optimized for; 1) high target selectivity; 2)
novelty (freedom to operate); and 3) applicability, efficacy (clinical
Additional NP-Epidrug highlights include:
- Improved target selectivity and thus enhanced therapeutic efficacy/safety profiles.
potential for improving current cancer therapies as well as advancing
cancer-related differentiation therapies into new markets.
- Potential as first in class/best in class therapies for type 2 diabetes and obesity.
- Design/Synthesis/Characterization by world renowned medicinal chemistry CRO's.
- PIER and NP-Reprog driven technology.
- Strong IP support.
NuPotential has identified several selective NP-Epidrugs
within its current libraries as therapeutic candidates for type 2
diabetes, obesity and cancer. Following successful preclinical
evaluation, lead compounds will be navigated into clinical trials.
NuPotential welcomes the opportunity to discuss potential
collaborative and/or strategic partnerships to advance lead NP-Epidrugs into clinical studies and beyond.
Louisiana Emerging Technology Center, 340, E. Parker Blvd., Baton Rouge, LA 70803 • 225/615-8955
Copyright© 2012 NuPotential, Inc. All rights reserved.